Stockscreener 앱 받기
1.80
1.64%
-0.03
시간 외 거래:
1.82
0.02
+1.11%
전일 마감가:
$1.83
열려 있는:
$1.84
하루 거래량:
1.00M
Relative Volume:
0.34
시가총액:
$179.60M
수익:
-
순이익/손실:
$-37.34M
주가수익비율:
-1.3235
EPS:
-1.36
순현금흐름:
$-36.91M
1주 성능:
+1.69%
1개월 성능:
-2.70%
6개월 성능:
+78.22%
1년 성능:
+55.17%
1일 변동 폭
$1.78
$1.86
1주일 범위
$1.75
$1.94
52주 변동 폭
$0.772
$2.2691
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
명칭
Sellas Life Sciences Group Inc
전화
(646) 200-5278
주소
7 TIMES SQUARE, NEW YORK, NY
SLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
1.80 | 182.59M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-07-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-11-01 | 개시 | Oppenheimer | Outperform |
| 2018-04-02 | 개시 | H.C. Wainwright | Buy |
| 2018-03-19 | 업그레이드 | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc 주식(SLS)의 최신 뉴스
What analysts say about SELLAS Life Sciences Group Inc. stockExplosive portfolio gains - Autocar Professional
SELLAS Life Sciences Group Inc. Stock Analysis and ForecastTriple-digit profit margins - PrintWeekIndia
What institutions are buying SELLAS Life Sciences Group Inc. stock nowStrong return on assets - jammulinksnews.com
What drives SELLAS Life Sciences Group Inc. stock priceFree Stock Market Real-Time Monitoring - Autocar Professional
Is SELLAS Life Sciences Group Inc. a good long term investmentTurbocharged investment results - jammulinksnews.com
What drives USEA stock priceMassive wealth growth - jammulinksnews.com
What makes SELLAS Life Sciences Group Inc. stock attractive to long term investorsMomentum Swing Watchlist - beatles.ru
SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Expected to Rise, Maxim Group Analyst Says - Defense World
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities - Finansavisen
Sellas Life Sciences shares fall 1.58% premarket after meeting primary endpoints in Phase 2 trial. - AInvest
SELLAS Meets All Primary Endpoints in Phase 2 Trial of - GlobeNewswire
Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success - insights.citeline.com
What makes SELLAS Life Sciences Group Inc. stock price move sharplyReal Time Breakout Tracking - Newser
How SELLAS Life Sciences Group Inc. stock performs during market volatilityHigh Yield Opportunities - Newser
Sellas Flat on Trial Success - Baystreet.ca
Sellas Life Sciences Meets Primary Endpoints in Mid-Stage SLS009 Trial - MarketScreener
SELLAS gains on mid-stage trial win for leukemia drug (SLS) - Seeking Alpha
SELLAS' Phase 2 Study Of SLS009 In Acute Myeloid Leukemia Meets All Primary Goals - Nasdaq
Why SELLAS Life Sciences Group Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser
SELLAS Life Sciences Group Reports Positive Phase 2 Trial Results for SLS009 in Relapsed/Refractory Acute Myeloid Leukemia - Nasdaq
SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study - The Manila Times
SELLAS Life Sciences Soars 14.21% on Key Appointment - AInvest
SELLAS Life Sciences Group Inc (SLS) Stock: A Year of Market Movement, Down and Up - investchronicle.com
Sellas Life Sciences Group Inc (SLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.97%
0.22%
자본화:
|
볼륨(24시간):